Genzyme ($GENZ) meets FDA consent decree deadline

Genzyme ($GENZ), subject to a hostile bid by Sanofi-Aventis ($SNY), said it has satisfied a key component of a consent decree imposed by U.S. regulators after a crisis at its Boston manufacturing facility led to shortages of two key drugs. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.